To study the cellular immunology of platelet-induced alloimmunization, a murine transfusion model was developed. BALB/c (H-2d) recipient mice were transfused weekly with 2 x IOs platelets or 10' leukocytes from C57BL/6 (H-2b) donor mice. Recipient antidonor major histocompatibility complex (MHC) class I alloantibodies could be detected in flow cytometric assays by the fifth platelet transfusion. In contrast, when leukocytes only were transfused, alloantibodies were not detected. In vitro assays demonstrated that murine H2b platelets were positive for MHC class I expression but lacked MHC class II molecules on their membranes and were unable to stimulate prolieration or cytokine production when incubated with naive H-2d spleen cells. In vivo, however, platelet transfusions induced two distinct patterns of cell-mediated reactivity. First, during the initial transfusions and before alloantibody formation, there was induction of T-cell anergy, characterized by the inability of recipient T cells to respond to Concanavalin A (ConA) or to proliferate in an antidonor mixed lymphocyte reaction (MLR), together LLOIMMUNIZATION is a clinically significant adverse reaction associated with blood transfusion and organ transplantation. With respect to platelet transfusions, the generation of anti-HLA class I antibodies can lead to a state of clinical refractoriness to subsequent random donor platelet transfusions.'.' The production of antidonor cytotoxic T lymphocyte (CTL) or anti-class I major histocompatibility complex (MHC) antibodies during alloimmunization is primarily initiated by the direct recognition of class I1 MHC molecules on donor antigen-presenting cells (APC) by recipient T helper lymphocyte^.^.^ This mechanism is also postulated to be true for platelet transfusions.6 Thus, strategies to eliminate or reduce APC in platelet concentrates, (eg, leukofiltration) have been developed and are extensively used in clinical medicine. The efficacy of such leukofiltration methods to reduce or prevent alloimmunization remains, however, controversial.'
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To study the cellular immunology of platelet-induced alloimmunization, a murine transfusion model was developed. BALB/c (H-2d) recipient mice were transfused weekly with 2 x IOs platelets or 10' leukocytes from C57BL/6 (H-2b) donor mice. Recipient antidonor major histocompatibility complex (MHC) class I alloantibodies could be detected in flow cytometric assays by the fifth platelet transfusion. In contrast, when leukocytes only were transfused, alloantibodies were not detected. In vitro assays demonstrated that murine H2b platelets were positive for MHC class I expression but lacked MHC class II molecules on their membranes and were unable to stimulate prolieration or cytokine production when incubated with naive H-2d spleen cells. In vivo, however, platelet transfusions induced two distinct patterns of cell-mediated reactivity. First, during the initial transfusions and before alloantibody formation, there was induction of T-cell anergy, characterized by the inability of recipient T cells to respond to Concanavalin A (ConA) or to proliferate in an antidonor mixed lymphocyte reaction (MLR), together LLOIMMUNIZATION is a clinically significant adverse reaction associated with blood transfusion and organ transplantation. With respect to platelet transfusions, the generation of anti-HLA class I antibodies can lead to a state of clinical refractoriness to subsequent random donor platelet transfusions.'.' The production of antidonor cytotoxic T lymphocyte (CTL) or anti-class I major histocompatibility complex (MHC) antibodies during alloimmunization is primarily initiated by the direct recognition of class I1 MHC molecules on donor antigen-presenting cells (APC) by recipient T helper lymphocyte^.^.^ This mechanism is also postulated to be true for platelet transfusions.6 Thus, strategies to eliminate or reduce APC in platelet concentrates, (eg, leukofiltration) have been developed and are extensively used in clinical medicine. The efficacy of such leukofiltration methods to reduce or prevent alloimmunization remains, however, controversial. ' Several transfusion-based experimental animal models have shown that transfusions elicit in vivo immunomodulatory effects in the recipient ani mal^.'"^ Most of these models have, however, used whole blood or mixtures of cell types as the transfusate, and few have examined specific blood components. In murine studies, for example, Blajchman et all5 have shown that allogeneic whole blood transfusions can enhance the in vivo growth of a syngeneic fibrosarcoma in recipient mice and that leukoreduction removes the tumor growth-promoting activity of the transfusion. On the other hand, in 1992, Kao16 demonstrated that leukoreduced [less than three white blood cells (WBCs) per microliter] murine platelets were immunogenic when transfused weekly into allogeneic recipients; anti-MHC antibodies could be detected in the sera of recipient mice by the fourth week of transfusion. This was in contrast to an earlier report that suggested that platelets were nonimmunogenic and require at least lo3 contaminating leukocytes to elicit an anti-MHC response." Using a murine model of platelet-induced alloimmunization, we have found that repeated leukoreduced platelet transfusions induce an antidonor MHC class I IgG antibody with suppressed natural killer (NK) cell activity. This unresponsiveness was associated with a transient increase in nitric oxide (NO)-dependent cytotoxicity and interleukin-l (IL-l) production. Second, once alloantibodies developed, significantly increased antidonor CD8+ cytotoxic T lymphocyte (CTL) and NK cell responses were observed. At this time, when recipient spleen cells were depleted of CD8' T cells and incubated with only donor platelets in 7-day antigen-presenting cell (APC) assays, enhanced proliferation and 11-2 production occurred. These cellular responses were not seen when IO3 allogeneic leukocytes were transfused. Thus, the results suggest that leukoreduced platelet transfusions induce antidonor MHC antibodies and CD8' CTL responses in recipient mice. At the same time, the transfusions induced recipient CD4' T-cell activation when incubated with donor platelets in the presence of syngeneic APCs, an indirect recognition pathway that correlates with the time of alloantibody production. 0 7995 by The American Society of Hematology.
response by the fifth transfusion. At the same time, antidonor CD8' CTL and CD4+ T-cell antidonor platelet reactivity could be measured from recipient spleens. These results suggest that leukoreduced platelet transfusions can elicit their immunogenicity via an indirect allorecognition mechanism.
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SEMPLE ET AL vitro assays were maintained in RPMI-1640 with 5% fetal calf serum (FCS), 100 pg/mL penicillin/streptomycin/fungizone, 100 m m o w L-glutamine, and 5 X m o m 2-mercaptoethanol. Cell preparation and transfusion protocol. Spleen cells were used as a source of WBCs. Briefly, mice were killed, and spleens were removed and teased into single-cell suspensions. The cells were layered on a 1.080-g/mL Percoll cushion, and WBCs were enriched by centrifugation at 1,800g for 30 minutes at 20°C. To standardize WBC numbers for injections, the cells were washed four times, adjusted to 106/mL, and diluted IO-fold to 104/mL. For platelets, mice were bled via the tail vein (approximately 200 p1 per bleed) into EDTA-microvettes (Starstedt, St Laurent, Quebec, Canada) that were dipped in a 20-U/mL heparin solution. The blood was pooled and centrifuged at 120g and the platelet-rich plasma (PRP) was aspirated off, care was taken not to disturb or aspirate the buffy coat. The platelets were washed three times in EDTA-saline, and contaminating leukocytes were enumerated. Platelets were adjusted to 2 X lO'/mL. Each transfusion protocol began with 55 recipient mice; the mice were bled 24 hours before transfusion and injected (100 pL) via the tail vein with either 2 X loH platelets or IO3 WBCs.
The number of platelets transfused in these studies approximates the average number of platelets (on a blood volume basis) that would normally be given during one transfusion in humans (ie, 4 X IO" to 5 X 10" platelets). Every week, a group of five mice were killed, and their spleens were removed for in vitro cellular assays, while the remaining mice were transfused.
Enumeration of contaminating leukocytes. To count the low numbers of contaminating WBCs in the platelet concentrates, a Nageotte hemocytometer (Baxter, Chicago, L) was used, and the counts were confirmed by flow cytometry using hypotonic lysis and propidium iodide (PI). Briefly, 200 pL of platelets to be transfused were stained with Turk's solution for 30 minutes at 20"C, the suspension was added to a Nageotte hemocytometer, and the nuclei were counted in all the rows. This method allows for the accurate enumeration of approximately one WBC per microliter. For flow cytometric determinations of leukocyte contamination, a modification of the method of Kao and Scornikl' was used. Briefly, 200 pL of the platelet concentrate were added to a 1.5-mL Eppendorf tube and centrifuged at 5,OOOg for 5 minutes, and 100 pL of buffer [l mgl mL sodium citrate, 0.03% (voUvol) Triton X-100, 50 pglmL PI, IO mg/mL RNAse] was added to the platelet pellet at 25°C in the dark. Within 30 minutes, the total volume was acquired on a FACSort flow cytometer (Becton Dickinson, San Jose, CA), and PI fluorescence was analyzed using single histogram analysis. Fluorescent markers were set on PI fluorescence determined from a standard 10-fold dilution of similarly prepared WBCs (5 X 103/pL to O.O5/pL). This method detected 50.5 WBCs per microliter. Both methods gave comparable results and demonstrated that the average leukocyte contamination in the platelets transfused was 1.8 ir 3.8/pL (range, less than 0.5 to lO/pL; N = 30). Thus, all platelet concentrates in this study are considered leukoreduced; ie, equivalent to less than 1.5 x IO5 to 3 x lo6 WBCs in a 300-mL pooled platelet concentrate containing 5 X IOLL platelets.
Flow cytometric analyses. For detection of MHC antigens, platelets were washed three times, and IO5 cells were incubated with 1 pg (100 pL total) of either affinity-purified monoclonal anti-class I1 I-Ab or anti-class I Kb antibody (Cedarlane Laboratories, Hornby, Ontario, Canada) for 45 minutes at 20°C. washed twice, and stained with a U100 dilution of phycoerythrin (PE)-conjugated goat antimouse IgG (GAM-PE, Fc-specific; Cedarlane). Platelets were also labeled with fluorescein isothiocyanate (FITC)-conjugated anti-murine b3 integrin (CD61; Phannagen Laboratories, San Diego, CA) and acquired through a live gate drawn on forward light scatter (FSC) and F L l fluorescence. Fluorescent analysis of 50,000 events was performed using single histograms. In some experiments, PEconjugated anti-CD61 was used for detecting platelets in single label studies.
For characterization of recipient sera, IO5 donor or recipient WBCs, platelets, EL-4 or P815 cell lines were incubated with the indicated dilutions of recipient sera for 30 minutes at 20°C. washed once, labeled with FTTC-conjugated goat antimouse IgG (GAM-FITC, Fc-specific; Cedarlane), and analyzed flow cytometrically. Using a live lymphocyte or platelet gate, 10,OOO events were acquired. Matched pre-bleed serum was used as the negative control in all experiments, and FITC-conjugated anti-Kb or anti-Kd monoclonal antibodies (Cedarlane) were used as positive controls.
Cell depletion with monoclonal antibodies. WBCs were depleted of helper or suppressorkytotoxic T cells by incubation with anti-L3T4 (CD4) or anti-Ly 2.2 (CD8a) monoclonal antibodies (Cedarlane). Briefly, 2 pg of either antibody was incubated with 2.5 X lo7 cells for 30 minutes at 4"C, washed once, and then incubated with a 1/20 dilution of rabbit complement (Cedarlane) for 30 minutes at 37°C. Viability was determined by Trypan blue exclusion; by this method, greater than 93% of the CD4+ or CD8+ T cells were killed. The remaining viable cells were washed once and used in the indicated cellular assay.
Cell culture. Proliferative ability of recipient spleen cells was assessed in 48-hour mitogen assays using either Concanavalin A (ConA) or lipopolysaccharide (LPS; Sigma Chemical CO, St Louis, MO). Recipient WBCs (2 X 10' per well) were incubated in 96-well, flat-bottom plates with the indicated concentrations of mitogen in 200 pL triplicate cultures for 24 hours at 37°C. The cultures were then pulsed with 1 pCi ['Hlthymidine and incubated a further 24 hours. Wells were harvested onto filter paper, and incorporated cellular radioactivity was measured in a @-counter (Pharmacia-LKB, Mississauga, Ontario, Canada).
Direct recognition of allogeneic class I1 MHC was measured by 72-hour mixed lymphocyte reaction (MLR) cultures. Donor spleen cells were y-irradiated with 2,500 cGy using a I3'Cs source (Atomic Energy of Canada, Chalk River, Ontario, Canada) and were used as stimulators. Recipient spleen cells (2 X l@) were mixed with the indicated concentrations of stimulators in 250 pL triplicate cultures in 96-well, flat-bottom plates (Falcon; Becton Dickinson, Mississauga, Ontario, Canada) and incubated for 48 hours at 37°C. Supernatants (150 pL) were then removed and stored at -80°C. The cells were pulsed with 1 pCi of ['H]thymidine for an additional 24 hours, and incorporated cellular radioactivity was measured.
Indirect recognition of allogeneic platelets was measured in 7-day APC assays containing syngeneic recipient APCs and T cells and allogeneic donor platelets. In round-bottom plates (Falcon), 2 X IO5 recipient WBCs were mixed with titrations (from 12.5 X lo6 to 1.5 x IO5) of donor platelets in 250 pL triplicate cultures for 6 days at 37°C. Supernatants were removed, the cultures were pulsed with [3H]thymidine for 24 hours, and incorporated cellular radioactivity was measured.
Cell-mediated cytotoxicity was measured using recipient spleen cells as effector cells in 6-or 18-hour cytotoxicity assays using the three "Cr-labeled target lines, YAC-1, EL-4, and P815. Recipient WBCs were titrated in triplicate in 96-well, V-bottom plates (Falcon) to make final effector-to-target (E:T) ratios of 1 W 1 to 0.75: 1. Target cells were labeled (100 pCi sodium5' chromate per IO6 cells) for 1 hour at 37"C, washed five times, and used at 5,000 cells per well. Target minimum and maximum cytolysis was determined for targets, and percent lysis was determined by the formula: cp-, -cpmni.l cpm,,,, -cpm,,,,, x 100. Spontaneous "Cr-release never exceeded 10%. N-Monomethyl-L-arginine (NMma; Calbiochem, La Jolla, CA), an inhibitor of nitric oxide (NO) synthase, was added to the 5'Cr-release assays (1 mmoVL final) to characterize the cytotoxicity. natants were added to 1 X lo4 starved CTLL cells. The cells were incubated for 18 hours at 37T, pulsed with 1 pCi [3H]thymidine, and incubated a further 6 hours, and incorporated radioactivity was determined. L 4 and IFN-7 were measured by commercial enzymelinked immunosorbent assays (ELISAs; Cedarlane Laboratories and Immunocorp, Montreal, Quebec, Canada, respectively). IL-lP was also measured in the sera of recipient mice by ELISA (Cedarlane). Standard curves were generated with titrations of recombinant cytokines.
Staristical methods. Significant differences between means were determined by the Student's t-test.
RESULTS
In vivo humoral responses to allogeneic platelet transfusions. To detect the development of antidonor antibodies in the recipient mice, flow cytometric analysis with recipient sera and donor WBCs was performed. The panels of histograms in Fig 1 show typical results (Fig 19) . However, if only lo3 H-2b WBCs were transfused, antidonor antibodies were not detected within the IO-week transfusion protocol ( Fig  1D) . Figure 1C shows that antidonor alloantibodies were detected by the fifth transfusion of H-2' allogeneic platelets. Thus, leukoreduced allogeneic platelet transfusions can induce the formation of antidonor antibodies. The recipient sera reacted strongly with H-2b EL-4 cells but not with H2d P815 cells, and could neutralize the binding of a PEconjugated monoclonal anti-class I H-2K' antibody to donor WBCs (not shown). Thus, the antidonor antibodies were directed against class I MHC determinants.
In vitro characterization of platelet phenotype and stimulation of allogeneic recipient WBCs. To ensure that murine platelets express MHC molecules and to determine their baseline ability to stimulate allogeneic WBCs, in vitro assays were performed. Figure 2A demonstrates that murine platelets are reactive with anti-class I MHC antibodies but not with anti-class I1 antibodies. The anti-class I reactivity with the H-2' platelets was, however, lower than that seen when H-2b WBCs were used (not shown). Figure 2B shows that platelets with this MHC phenotype could not stimulate allogeneic WBCs to proliferate in a 7-day APC assay. Thus, murine platelets are class I MHCpositive, class I1 MHC-negative, and cannot stimulate the proliferation of naive allogeneic WBCs in vitro.
Mitogen stimulation of the recipient WBCs. The effect of platelet transfusions on T-and B-cell proliferative responses was analyzed by mitogen assays. Figure 3A shows that after one allogeneic platelet transfusion, the ability of recipients' WBCs to respond to the T-cell mitogen ConA was significantly inhibited (P < .001) but subsequently returned to normal levels by the third transfusion. In contrast to allogeneic platelet transfusions, transfusion of io3 allogeneic WBCs caused only a small, gradual reduction of ConA responses of recipients' WBCs (Fig 3B) .
Proliferative responses of the WBCs of recipient mice to the B-cell mitogen LPS were also elevated (P < .02) at the second platelet transfusion but not affected by the allogeneic WBC transfusions (Fig 3A and B, respectively) . Thus, platelet transfusions enhance B-cell responsiveness to mitogens. Cell-mediated cytotoxicity in the transfusion recipients. As murine platelets were found to be class I-positive and induce the formation of alloantibodies, we studied how they affected three different cell-mediated cytotoxicities: natural killer (NK) cell activity against YAC-1 targets, alloreactivity against EL-4, and autoreactivity against P815. As seen in Fig 4A, during the initial platelet transfusions (transfusions  1 through 3) , before development of alloantibodies (at transfusion S), NK cell cytotoxic activity was markedly suppressed, and both alloreactive and autoreactive cytotoxicity were, in contrast, transiently stimulated. At week 5, the time of alloantibody formation, however, all three cytotoxic responses were significantly stimulated in platelet transfused For personal use only. on November 11, 2017. by guest www.bloodjournal.org From by NMma; it was not inhibited by anti-CD8 depletion, and similar results were seen for the initial platelet-induced autoreactive cytotoxicity (not shown). Figure 5B shows that the second wave of platelet-induced alloreactive cytotoxicity (at transfusion 5 ) was only inhibited if the recipient spleen cells were first depleted of CD8+ T cells by anti-CD8 antibody and complement. This was also true for the autoreactive cytotoxicity at this time (not shown). In contrast, the WBC transfusion-induced cell-mediated cytotoxic activities at both one and eight transfusions could be partially inhibited (approximately 50%) by depletion of CD8+ T cells and also by NMma (approximately 40%; not shown).
Direct recognition of donor MHC class 11 during platelet
transfusions. Three-day MLR cultures were used to assess the effect of transfusions on direct recognition of allogeneic donor class I1 MHC molecules by recipient CD4+ T helper cells. Figure 6A shows that the ability of WBCs from recipient mice transfused with platelets to proliferate after stimulation with irradiated donor WBCs cycled during the course of platelet transfusions: it was markedly inhibited by the second transfusion (P < .001), subsequently increased to pretransfusion levels by the sixth transfusion and, then began 301 mice compared with the previous week (P < .W1 for NK, P < .001 for allo-CTL, and P < .05 for auto-CTL). Figure   4B shows that, in mice transfused with allogeneic WBCs, NK activity, autoreactive cytotoxicity, and alloreactive cytotoxicity initially responded in a similar but more gradual fashion after the initial WBC transfusions (weeks 1 through 3). By eight WBC transfusions, stimulation of the three cytotoxicities was again seen (Fig 4B) .
To characterize whether the stimulated cytotoxicities shown in Fig 5 were due to NO generation or by CD8+ T cells, "Cr-release assays were performed either in the presence of NMma or with CD8-depleted recipient spleen cells. Figure 5A shows that the initial (after one transfusion) platelet-induced alloreactive cytotoxicity could only be inhibited to decrease again by the ninth transfusion. Similar results were seen when third party (H-2') stimulators were used in the MLR assays (not shown). In contrast to platelet transfusions, transfusions with allogeneic WBCs did not affect the MLR response of recipient WBCs at any time (Fig 6B) . Thus, allogeneic platelet transfusions can significantly alter CD4+ T-cell responses in an antidonor MLR.
Assessment of indirect allorecognition of donor platelets. To test whether the transfusions could prime recipient WBCs in vivo to respond to allogeneic platelets in vitro, 7-day APC assays were used. As seen in Fig 6A and B , allogeneic platelets could not stimulate unfractionated recipient WBCs to proliferate at any time during either the platelet or WBC transfusion protocol. However, when the recipient WBCs were depleted of CD8+ T cells by anti-CD8 antibody and complement before culturing, antiplatelet proliferative activity could be detected by the fifth platelet transfusion ( Fig  6A) . Thus, leukoreduced platelet transfusions can stimulate CD8-depleted WBCs at the time of alloantibody production.
Cytokine responses during platelet transfusions. Cytokine assays were performed on the culture supernatants of the MLR and APC assays to further characterize the responding T-cell populations. Table 1 shows that during the 809 platelet transfusions, IL-2 production in the culture supernatants of the antidonor MLR was directly proportional to the CD4+ T-cell proliferative activity seen in Fig 6A. On the other hand, IL-4 production was not detected in any of the culture supernatants (MLR or APC) tested. IFN-y production could also be detected in some of the MLR supernatants and could be found in a proportion of the CD8-depleted APC cultures (Table l) . Thus, allogeneic platelet transfusions can stimulate Thl CD4+ T cells to proliferate and secrete IL-2 after in vitro donor platelet stimulation.
Serum IL-1 levels were quantitated in recipient mice. As shown in Table 1 , maximal L-1 production could be detected in the platelet-transfused mice during the first and second transfusion. For Figure 2A shows that the same is true for H-2b murine platelets. Correlated with these phenotypic observations, Fig 2B demonstrates that H-2b platelets lack the in vitro ability to stimulate proliferation or IL-2 generation (not shown) by allogeneic H-2d naive T cells. This result was also seen using a number of different allogeneic H-2 haplotype combinations (not shown) and may have relevance to other in vivo studies in mice that have demonstrated prolonged pancreatic islet cell survival after allogeneic donor-specific platelet transfus i o n~.~~ Interestingly, in human studies, Pocsik et alZ8 demonstrated that allogeneic, leukoreduced platelet transfusions in normal healthy men induced T-lymphocyte activation, particularly with respect to increased levels of IL-2 receptor expression. Thus, although leukoreduced platelets have no in vitro stimulatory ability for naive T cells, it appears that, For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From in vivo, they can induce both immunosuppressive and immunostimulatory effects.
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Our results partially support the work of Claas et all' in that transfusions of 103 allogeneic WBCs did not induce a detectable alloantibody response. The failure to detect WBCinduced alloantibodies may be due either to the numbers of WBCs being below the immunogenic threshold for BALB/ c mice, or to the induction of immune tolerance. Interestingly, in contrast to leukoreduced platelet transfusions, most of the cellular immune responses were not significantly altered during the WBC transfusions, except for the cytotoxicity patterns. This latter point suggests that transfusions of lo3 WBCs have some effect on cellular immune mechanisms in the recipients, but its relevance to antibody production or tolerance induction is unknown. Collectively, these findings suggest that, in immunocompetent hosts, leukoreduced platelets are potent stimuli for the production of anti-MHC alloantibodies.
Significantly different cell-mediated responses could be observed in relation to the development of alloantibodies in the platelet-transfused recipient mice. The initial platelet transfusions, before alloantibody development, markedly inhibited the ability of recipient WBCs to respond to the pan-T-cell mitogen ConA or to irradiated donor stimulators. Because platelets are class I-positive but lack class 11 molecules, they should preferentially interact with only alloreactive CD8+ T cells. The fact that virtually all T cells, both CD4+
and CDV, were transiently paralyzed by the initial platelet transfusion suggests that additional, more generalized inhibitory mechanisms may initially occur. The T-cell inhibition was, however, transient, and normal ConA and MLR responses were restored by the third and fourth transfusions, respectively. We are studying whether this recovery is due to either a reversal of unresponsiveness within the T cells themselves or turnover of nascent T-cell precursors from the bone marrow.
Correlated with these findings were the recipient cytotoxicity patterns. The initial platelet transfusion significantly inhibited NK activity, and similar results were seen when lb WBCs only were transfused, except that the suppression occurred more gradually. Reduced NK activity after blood transfusions has been reported in human^'^.^' and may be due to NK cells being sensitive to insults such as stre~s.~' Interestingly, however, at the same time, both alloreactive and autoreactive cytotoxicities were stimulated, and characterization with NMma showed that it was NO synthasedependent. NO-dependent cytotoxicity of tumor cells, at least, is primarily mediated by macrophage^^^^'^ which have also been shown to be potent inhibitors of NK-mediated cytolysis.34 In addition, the sera from recipient mice contained measurable levels of E-l (Table l) , a potent mediator of inflammati~n.~' These results suggest that the initial platelet transfusions may stimulate macrophage activation, possibly via an inflammatory-like process. It is possible that the macrophage activation is responsible for the T-cell and NK cell unresponsiveness during the initial transfusions, eg, either by direct cytolysis of T-cell subsets or by secretion of inhibitory cytokines. Additionally, the source of IL-1 is not clear; ie, whether it is derived from the activated macrophages or, as murine platelet membranes have been shown to contain IL-1 precursor proteins?6 from the transfused platelets.
At the time of alloantibody formation (5 weeks) in the recipients, the ability of CD4+ T cells to directly recognize donor class I1 MHC molecules, proliferate, and secrete IL-2 in an MLR had recovered to normal levels. In addition, significant NK cell and CD8+ CTL (both allo-CTL and auto-CTL) cytotoxicities were stimulated. In subsequent weeks, however, these responses began to decrease. It is unknown why this apparent cycling of reactivities occurs, but it may be due to immunoregulatory mechanisms, particularly, to prevent autoreactive cytotoxicity. Nevertheless, alloreactive CTL cytotoxicity remained elevated for the duration of the transfusion protocol. In humans, transfusions have been shown to induce autoreactive cytotoxicity mediated by both CD4+ class 11-restricted and CD8' class I-restricted CTL.37 It is possible that the autoreactive cytotoxicity seen at the fifth transfusion in our studies is due to the highly stimulated alloreactive CTL crossreacting with self-MHC molecules. The alloreactive CTLs generated by the platelet transfusions suggest the intriguing possibility that class I-positive platelets can prime CTL precursors in vivo. However, as alloreactive CTLs require T-cell helper activity for their development,5 platelet transfusions should, at some point, generate CD4+ T cells.
Indirect recognition of donor platelets in the APC assays was not observed at any time during either the platelet or WBC transfusion protocols when unfractionated recipient spleen cells were used as responders. However, in the platelet transfusion recipients, if spleen cells were depleted of CD8' T cells before culture with allogeneic platelets, proliferation and IL-2 production were seen at the time of alloantibody production. This suggests that platelet transfusions can prime recipient antiplatelet CD4' T cells in vivo and, as platelets have no in vitro APC function (Fig 2) , indicates that antiplatelet CD4+ T-cell reactivity in the APC assays may be stimulated through an indirect mechanism. We are currently testing whether MHC peptides derived from murine platelets can mimic this in vitro response. In addition, these observations indicate that CD8+ T cells are present in the spleens of the platelet-transfused mice, which may inhibit CD4+ T cells. These results support previous observations that have identified T suppressor activity during blood transfusions.'"' Thus, the data presented suggest that allogeneic, leukoreduced platelets are immunogenic with respect to anti-class I antibody formation and antidonor CTL generation, and these responses are induced by indirect recognition of platelet-derived all0 (MHC class 1) antigens on syngeneic APCs by recipient CD4+ T cells.
